Pathology & Biopsy Results

A biopsy is the only test that can definitively confirm whether a breast finding is cancer. When a radiologist or surgeon takes a sample of breast tissue - using a needle or during surgery - a pathologist (a physician who specializes in diagnosing disease by examining tissue under a microscope) analyzes the sample and writes a detailed report. This is your pathology report.

The pathology report is the foundation of your entire treatment plan. Every recommendation your oncologist, surgeon, and radiation oncologist makes - chemotherapy, surgery, hormone therapy, targeted therapy - is shaped by what your pathology report says. Asking for a copy of your report and learning to read it is one of the most empowering things you can do as a patient.

The single most important question your biopsy answers is whether the cells found are benign (not cancer) or malignant (cancer). Most breast biopsies - about 80% - are benign. But if your biopsy returns a malignant result, it is important to understand precisely what that means.

The hormones estrogen and progesterone - produced naturally in your body - play a key role in regulating the growth of normal breast cells. They do this by binding to specific receptor proteins inside cells, like a key fitting into a lock. When the hormone (the key) attaches to the receptor (the lock), it activates signals telling the cell to grow and divide.

In about 70–80% of breast cancers, the cancer cells still carry these receptors. When they do, the tumor is using estrogen or progesterone as a fuel source to grow. This is extremely important information because it means the cancer can be treated with medicines that either block the receptor or reduce the body's estrogen production - a type of treatment called hormone therapy (or endocrine therapy). Hormone therapy is one of the most effective, best-tolerated, and widely used treatments in breast cancer care.

Your pathology report will always include the results of three key receptor tests: ER (estrogen receptor), PR (progesterone receptor), and HER2 (human epidermal growth factor receptor 2). Together, these three markers define the molecular subtype of your cancer - and largely determine which treatments will be most effective.

Histologic grade (also called tumor grade or Nottingham grade) describes how different the cancer cells look from normal breast cells under a microscope - and therefore, how aggressively they are likely to behave. Normal cells look organized, structured, and uniform. The more a cancer cell looks like a normal cell, the lower the grade; the more abnormal, chaotic, and primitive it looks, the higher the grade.

Grade is determined using the Nottingham grading system, which scores three features on a scale of 1–3 each: (1) tubule formation, (2) nuclear pleomorphism - how variable and abnormal the cell nuclei look, and (3) mitotic count - how many cells are actively dividing. These three scores are added to give a total of 3–9, which translates to Grade 1, 2, or 3.

Ki-67 is a protein present in cells that are actively dividing. Pathologists measure the Ki-67 index using IHC staining - it is reported as the percentage of tumor cells that are actively dividing. The higher the percentage, the faster the cancer is growing.

Ki-67 is most useful for classifying hormone receptor-positive (HR+) cancers into Luminal A (low Ki-67 - slow growing, hormone therapy alone) versus Luminal B (high Ki-67 - faster growing, may need chemotherapy in addition to hormone therapy). It is also used to assess how well a cancer is responding to treatment before surgery.

When a surgeon removes a breast tumor - during a lumpectomy (breast-conserving surgery) or mastectomy - the pathologist examines the outer edges of the removed tissue. These edges are called surgical margins or resection margins. Margin assessment answers one critical question: Did the surgeon remove all of the cancer?

To make the edges visible, the pathologist "inks" the outer surface of the specimen - painting it with a colored dye. Then thin slices are cut through the specimen and examined under the microscope. The relationship between cancer cells and the inked edge determines the margin status.

Lymph nodes are small, bean-shaped structures that are part of your immune system. They act as filters for the lymphatic fluid that drains from body tissues. For breast cancer, the most important lymph nodes are those in the axilla (armpit) - called axillary lymph nodes. If breast cancer cells spread beyond the breast, they typically travel first through the lymphatic vessels into these nearby lymph nodes.

Lymph node status is one of the most important prognostic factors in breast cancer. It contributes directly to staging (T-N-M system) and influences decisions about chemotherapy and radiation.